Back to full list of clinical trials

Ongoing clinical trials for irritable bowel syndrome: Actively recruiting


Irritable bowel syndrome

Study title:

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Description of study:

We are doing this research study to find out if a new drug, JNJ-27018966, can help people with irritable bowel syndrome with diarrhea (IBS-d). People with IBS-d have abdominal discomfort or pain along with frequent diarrhea. We also want to find out if JNJ-27018966 is safe to take without causing too many side effects. The primary objectives of this study are:
• To evaluate the clinical response of patients with IBS-d to JNJ-27018966, relative to placebo.
• To evaluate the overall safety and tolerability of JNJ-27018966 in the treatment of IBS-d.

The secondary objective of this study is to further evaluate the treatment effect of JNJ- 27018966 relative to placebo based on patient reports of IBS-d symptoms (abdominal pain, abdominal bloating, stool consistency, global symptom scores, adequate relief), bowel functioning, and quality of life.

Basic eligibility criteria:

1. Between the ages of 18-80
2. Patients suffering from IBS-d (diarrhea predominant irritable bowel syndrome)
3. Suffering from abdominal pain, bloating, diarrhea

Principal Investigator:

Braden Kuo, MD


Shahar Castel; 617-726-0196

Back to Top